ArticleInternational journal of nanomedicine2025
Transplanted Iron Oxide Nanoparticle-Labeled Mesenchymal Stem Cells Exhibit ex vivo Neuronal Firing Activity in Ischemic Stroke Rats.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Mesenchymal stem cell (MSC) therapy shows promise in preclinical ischemic stroke models, yet clinical translation remains inconsistent. To address this gap, we investigated whether labeling MSCs with Ferucarbotran enables magnetic resonance imaging (MRI) tracking and enhances neural differentiation and functional integration, particularly focusing on the novel observation of spontaneous neuronal firing activity in transplanted cells. Methods: Rat MSCs (rMSCs) were transduced with red fluorescent protein (RFP) and labeled with Ferucarbotran to generate Fer-RFP⁺ rMSCs. These were transplanted into rats subjected to middle cerebral artery occlusion. MRI tracked cell migration and localization. Behavioral recovery was evaluated via the corner test, modified neurological severity score (mNSS), and infarct volume analysis. Post-transplantation, Fer-RFP⁺ rMSCs were magnetically isolated for ex vivo electrophysiological and immunocytochemical analyses. Results: Ferucarbotran labeling did not impair rMSC viability and enhanced in vitro proliferation. MRI effectively visualized Fer-RFP⁺ rMSC migration to ischemic regions. Rats receiving Fer-RFP⁺ rMSCs showed significantly improved functional recovery and reduced infarct volumes compared to controls. Remarkably, ex vivo isolated Fer-RFP⁺ rMSCs exhibited spontaneous neuronal firing on multi-electrode array recordings and expressed the neuronal marker NeuN. Conclusion: Ferucarbotran-labeled MSCs not only serve as MRI-visible tracers but also exhibit neuronal electrophysiological properties post-transplantation in an ischemic stroke model. The emergence of spontaneous neuronal firing in ex vivo transplanted MSCs suggests functional neuronal differentiation, potentially underpinning the observed therapeutic effects. These findings offer new mechanistic insights into MSC-mediated stroke recovery and may enhance the translational relevance of MSC-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.